DOXIMITY INC

Company Overview

Doximity is a physician‑focused digital platform that connects U.S. medical professionals and monetizes that network through subscription Marketing, Hiring, and Workflow solutions for pharmaceutical companies, health systems, and recruiting firms. The platform had over two million registered members (including >80% of U.S. physicians) and more than 620,000 unique providers used clinical workflow tools in the March 2025 quarter. Fiscal 2025 results showed $570.4M of revenue (driven ~entirely by subscriptions), $223.2M net income and adjusted EBITDA of $313.8M (≈55% margin), with key operating metrics including 119% net revenue retention and a growing cohort of large customers (116 customers >$500K TTM). The business is capital‑light and highly scalable, but exposed to healthcare data/privacy laws (HIPAA, state privacy statutes, TCPA), evolving AI regulation, and customer spending cyclicality.

Executive Compensation Practices

Compensation at Doximity likely emphasizes equity-heavy packages and performance pay: management discloses material stock‑based compensation ($72.4M in FY25) used for hiring and retention, and valuation of awards is a critical judgment area in the filings. Short‑ and long‑term incentives are plausibly tied to subscription growth, net revenue retention, ARPU (Marketing Solutions unit), adjusted EBITDA/cash flow and expansion within large customers (customers >$500K account for a large share of revenue). Given the company’s R&D focus and high percentage of employees in product roles, grants and retention RSUs/PSUs are likely common to retain technical talent and align incentives with product adoption metrics (workflow tool usage, member engagement). Accounting and tax issues (award valuation assumptions, capitalization of R&D, potential excise tax exposure from repurchases) can materially affect reported compensation expense and bonus/award sizing.

Insider Trading Considerations

High cash generation and an active $500M repurchase authorization (meaningful repurchases executed in FY25 and Q1 FY26) create liquidity that can both buoy the stock and be a context for insider selling; routine insider sales may be used to cover tax liabilities from equity awards rather than signal negative views. Expect insiders to rely on Rule 10b5‑1 plans and to be constrained by standard blackout windows around quarterly results, material product launches (e.g., Doximity GPT, major workflow rollouts), large customer renewals/expansions, M&A activity, or regulatory developments (privacy/AI enforcement). Material equity grants and the company’s disclosure of stock‑based compensation valuation judgments mean spikes in insider sales can follow sizable awards; researchers should watch timing relative to repurchase activity and key operating disclosures (net revenue retention, large-customer count, billing/collections) for interpretive context. Regulatory and healthcare compliance risks (HIPAA, anti‑kickback rules) also increase the likelihood that insiders will avoid trading ahead of regulatory or legal developments.